Previous 10 | Next 10 |
2023-05-11 14:12:03 ET Following a meeting of its expert advisors, the World Health Organization announced Thursday that the monkeypox outbreak would no longer be regarded as a public health emergency of international concern (PHEIC). Monkeypox virus, currently known as mpox, led to a g...
GAITHERSBURG, Md., May 11, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2023 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 25, 2023 at 9:00 AM EDT. HOW TO PARTICIPATE IN THE VIRTUAL ...
2023-05-10 19:34:02 ET Summary Emergent BioSolutions has seen a significant revenue decline and stock value drop within the past year. The FDA has approved Emergent's over-the-counter Narcan, a drug to treat opioid overdoses. OTC Narcan can contribute significantly to combatti...
2023-05-10 17:56:52 ET Summary For the month, the Singular coverage list underperformed the S&P 500 Index and the Russell 2000 by (507) and (174) basis points, respectively. Since our 2004 inception, the Singular coverage list has outperformed the S&P 500 and Russell 2000 ...
2023-05-10 03:00:19 ET Image source: The Motley Fool. Emergent BioSolutions (NYSE: EBS) Q1 2023 Earnings Call May 09, 2023 , 5:00 p.m. ET Operator Continue reading For further details see: Emergent BioSolutions (EBS) Q1 2023 Earnings Call...
2023-05-09 22:40:23 ET Emergent BioSolutions Inc. (EBS) Q1 2023 Earnings Conference Call May 09, 2023 05:00 PM ET Company Participants Bob Burrows - VP, IR Bob Kramer - President and CEO Paul Williams - Senior Vice President, Products Business Rich Lindahl - ...
2023-05-09 16:21:12 ET Emergent Biosolutions press release ( NYSE: EBS ): Q1 GAAP EPS of -$3.65. Revenue of $165M (-46.3% Y/Y). Shares -0.41% . Net loss of $183M and adjusted EBITDA of negative $101M Guidance FY: Total Revenues $1,100M - $1,200M; Net Loss $...
Reports Q1 2023 total revenues of $165M, above the prior guidance range, net loss of $183M and adjusted EBITDA of negative $101M Updates FY 2023 guidance and provides initial Q2 2023 guidance GAITHERSBURG, Md., May 09, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) toda...
2023-04-20 12:45:47 ET Contract manufacturer Emergent BioSolutions ( NYSE: EBS ) announced Thursday that its recently approved over-the-counter (PTC) opioid overdose therapy Narcan would be priced at around $50 per carton. In March, when the FDA approved the nasal spray for OT...
GAITHERSBURG, Md., April 19, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, May 9, 2023, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2023, recent business developments, revenue guidance for the second q...
News, Short Squeeze, Breakout and More Instantly...
Emergent Biosolutions Inc. Company Name:
EBS Stock Symbol:
NYSE Market:
Emergent Biosolutions Inc. Website:
New video and radio segments raise awareness of a potentially life-saving, three-step method that anyone can use to respond in a suspected opioid poisoning GAITHERSBURG, Md., July 24, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE: EBS) announced the launch of a new opio...
GAITHERSBURG, Md., July 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, August 6, 2024, at 5:00 pm eastern time to discuss the financial results for the second quarter 2024, key business updates, revenue guidance for the third quarter of...
The extension to a four-year shelf-life helps improve naloxone access as communities continue to grapple with the growing opioid epidemic; product with the extended shelf life has officially begun shipping WINNIPEG, Manitoba, July 22, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolution...